TOP > 外国特許検索 > OPHTHALMIC PHARMACEUTICAL COMPOSITION

OPHTHALMIC PHARMACEUTICAL COMPOSITION UPDATE

外国特許コード F180009616
整理番号 5491
掲載日 2018年11月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP023170
国際公開番号 WO 2017222042
国際出願日 平成29年6月23日(2017.6.23)
国際公開日 平成29年12月28日(2017.12.28)
優先権データ
  • 特願2016-125860 (2016.6.24) JP
発明の名称 (英語) OPHTHALMIC PHARMACEUTICAL COMPOSITION UPDATE
発明の概要(英語) The application provides an ophthalmic pharmaceutical composition containing a compound of formula (I) or an ester, oxide, prodrug, or pharmaceutically acceptable salt or solvate thereof contained in a high-density lipoprotein. In formula (I), Ra is selected from the group consisting of halogen, hydroxy, alkyl, halogen substituted alkyl, aryl, halogen or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halogen or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester, and cyano, and m is an integer selected from 0-4.
従来技術、競合技術の概要(英語) BACKGROUND ART
VCP(valosin-containing protein) ATPase 4 - having inhibitory activity of certain of the sulfonic acid derivative is -1 - - amino-naphthalene, intracellular ATP suppression of reduction, through suppression of the endoplasmic reticulum, a cytoprotective effect on the various cells, cell death (Patent Document 1) have an inhibiting effect, glaucoma, retinitis pigmentosa, age related macular degeneration or eye diseases such as ischemic ocular disease treatment and/or prevention are known to be effective (JP-2-4, 2 and Non-Patent Document 1). These diseases to the eye optic nerve and retinal tissue after damage to the present is, in general, after the agent by the eye of the eye is difficult to reach. In fact, a systemically administered by intraperitoneal administration of 4 - - amino-naphthalene sulfonic acid derivatives of the eye -1 - and/or treatment of a disease can be effective in the prevention is reported, when administered alone drops, after an amount sufficient to reach the eye has not been confirmed.
In recent years, drug delivery to the eye after the aim of improving the efficiency, the ophthalmic drug delivery carrier using the drug development has been attempted. The current applied to the ophthalmic drug as the carrier, after reaching the eye for known liposome (Patent Document 5 and 6). Reaches the eye after the smaller the size of the liposome, to increase the reachability of the eye after the expected (non-patent document 3) and, the size of the eye is preferably not more than 20nm for the carrier the drag indicates that a report (Non-Patent Document 4). However, generally less than 100nm of the size of the liposome can be manufactured with a small report.
Malignant tumor cells and cells for the purpose of delivery to the anticancer agent, the cell affinity peptides fuzed to a high-density lipoprotein (cHDL) has been known (Non-Patent Document 5). Drops as the target drug delivery, or less than 100nm particle size is not known of lipoproteins.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • IKEDA, Hanako
  • MURAKAMI, Tatsuya
  • KAKIZUKA, Akira
  • YOSHIMURA, Nagahisa
  • SUDA, Kenji
  • MIWA, Yuko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close